These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36346546)

  • 1. Atomoxetine Decreases Mitochondrial Biogenesis, Fission and Fusion In Human Neuron-like Cells But Does Not Alter Antioxidant Defences.
    Carreón-Trujillo S; Vázquez-González D; Corona JC
    Cell Biochem Biophys; 2023 Mar; 81(1):105-115. PubMed ID: 36346546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine produces oxidative stress and alters mitochondrial function in human neuron-like cells.
    Corona JC; Carreón-Trujillo S; González-Pérez R; Gómez-Bautista D; Vázquez-González D; Salazar-García M
    Sci Rep; 2019 Sep; 9(1):13011. PubMed ID: 31506604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1α Regulates Rotenone-Induced Dopaminergic Neurotoxicity.
    Peng K; Yang L; Wang J; Ye F; Dan G; Zhao Y; Cai Y; Cui Z; Ao L; Liu J; Zou Z; Sai Y; Cao J
    Mol Neurobiol; 2017 Jul; 54(5):3783-3797. PubMed ID: 27271125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy in Disruption of Mitochondrial Dynamics by Aβ (1-42) and Glia Maturation Factor (GMF) in SH-SY5Y Cells Is Mediated Through Alterations in Fission and Fusion Proteins.
    Ahmed ME; Selvakumar GP; Kempuraj D; Thangavel R; Mentor S; Dubova I; Raikwar SP; Zaheer S; Iyer S; Zaheer A
    Mol Neurobiol; 2019 Oct; 56(10):6964-6975. PubMed ID: 30949973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocoa beans improve mitochondrial biogenesis via PPARγ/PGC1α dependent signalling pathway in MPP
    Chidambaram SB; Bhat A; Ray B; Sugumar M; Muthukumar SP; Manivasagam T; Justin Thenmozhi A; Essa MM; Guillemin GJ; Sakharkar MK
    Nutr Neurosci; 2020 Jun; 23(6):471-480. PubMed ID: 30207204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity.
    Manczak M; Kandimalla R; Yin X; Reddy PH
    Hum Mol Genet; 2019 Jan; 28(2):177-199. PubMed ID: 30239719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
    Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
    Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
    Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
    CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of serum and brain superoxide dismutase levels depending on atomoxetine used in attention-deficit/hyperactivity disorder treatment: A combination of in vivo and molecular docking studies.
    Gür F; Gür B; Erkayman B; Halıcı Z; Karakoç A
    Bioorg Chem; 2020 Dec; 105():104435. PubMed ID: 33161254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
    Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary supplementation with acetyl-l-carnitine counteracts age-related alterations of mitochondrial biogenesis, dynamics and antioxidant defenses in brain of old rats.
    Nicassio L; Fracasso F; Sirago G; Musicco C; Picca A; Marzetti E; Calvani R; Cantatore P; Gadaleta MN; Pesce V
    Exp Gerontol; 2017 Nov; 98():99-109. PubMed ID: 28807823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
    Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
    Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
    Clemow DB; Nyhuis AW; Robinson RL
    CNS Neurosci Ther; 2016 Dec; 22(12):970-978. PubMed ID: 27476490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
    Smith T; Aman MG; Arnold LE; Silverman LB; Lecavalier L; Hollway J; Tumuluru R; Hyman SL; Buchan-Page KA; Hellings J; Rice RR; Brown NV; Pan X; Handen BL
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):868-876.e2. PubMed ID: 27663942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.